Skip to Content


Lauren May
Paul White

Using innovative approaches to revolutionise cardiovascular drug discovery

Cardiovascular disease is the cause of one in four deaths in Australia.

Adenosine receptor activation is the most powerful heart-protective mechanism currently known. However, its transition into the clinical setting is hindered by unwanted effects, such as decreased heart rate and low blood pressure.

The Cardiac GPCR Biology laboratory is working to bridge that gap by using innovative approaches to design new classes of drugs that will selectively enhance therapeutic, cardioprotective effects and minimise undesired harmful effects.